Contemporary Pharmacotherapy for OAB Broadcast (2018)
This activity is designed for the primary care provider and advanced practice provider who manage patients with overactive bladder. This activity will be based on an American Urological Association annual meeting course of the same name and will allow the faculty of that course to share additional thoughts and information directly to primary care and advanced practice providers.
This educational activity is supported by an independent educational grant from:
- Primary Care Physicians
- Advanced Practice Providers
After participating in this activity, learners will be able to:
- Define the similiarities and differences between the various oral pharmacotherapies for overactive bladder (OAB).
- Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.
- State the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
- Describe the potential future pharmacological pathways and therapies for OAB.
Overview of Overactive Bladder (OAB) Treatment Options:
- Oral Pharmacotherapies
- Beta-3 Agonists
- Combination Therapy
- What is Coming in the future?
- New FDA Approval
- Patient Engagement and Support
- What Should They Expect?
- How to Set Proper Patient Expectations
Victor W. Nitti, MD
Chair, AUA Office of Education
New York University Langone Medical Center
Disclosures: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Medtronic: Scientific Study or Trial
Eric S. Rovner, MD
Medical University of South Carolina
Disclosures: Astellas: Consultant or Advisor; Allergan: Consultant or Advisor, Scientific Study or Trial; Medtronics: Consultant or Advisor, Scientific Study or Trial; NextMed: Investment Interest; NIH/NIDDK: Scientific Study or Trial; Amphora: Consultant or Advisor, Scientific Study or Trial; ion innovations: Scientific Study or Trial; ipsen: Scientific Study or Trial; Velicept: Consultant or Advisor; Solace: Consultant or Advisor, Scientific Study or Trial; Roivant: Consultant or Advisor; Bluewind: Consultant or Advisor; eCoin: Consultant or Advisor, Scientific Study or Trial
Alan J. Wein, MD, PhD(hon), FACS
University of Pennsylvania
Disclosures: Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer; Axonics: Consultant or Advisor, Meeting Participant or Lecturer; Outpost: Consultant or Advisor, Meeting Participant or Lecturer; Velicept: Consultant or Advisor, Meeting Participant or Lecturer; Serenity: Consultant or Advisor, Meeting Participant or Lecturer; Aquinox: Consultant or Advisor, Meeting Participant or Lecturer; Avadel: Consultant or Advisor, Meeting Participant or Lecturer; Valencia: Consultant or Advisor, Meeting Participant or Lecturer; Urovant: Consultant or Advisor, Meeting Participant or Lecturer
Method of Participation
To claim CME credit/hours of participation, the learner must listen to the podcast, complete the post-test passing with 80% accuracy and submit the activity evaluation.
Estimated time to complete this activity: 1.00 hour
Release Date: May 19, 2018
Expiration Date: May 19, 2019
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AAFP Credit Designation: This Enduring Material activity, Contemporary Pharmacotherapy for OAB Broadcast (2018), has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 05/19/2018. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
AMA Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1.00 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
This educational activity is supported by an independent educational grant from Astellas.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation
- 1.00 AAFP Prescribed